GGrantIndex
Sort

48,018 grants matching immunotherapy

TARGETED IMMUNOTHERAPY FOR MELANOMA

$528,801
Georgia Tech Research Corp · · FY2016 · Department of the Army

Efficacious and safe antibody catalyzed amyloid beta clearance

$528,773
Sudhir Paul · University Of Texas Hlth Sci Ctr Houston · U01 · FY2010 · AG

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT

$528,762
Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2020 · CA

Immunosurveillance and Immunopathology Core

$528,724
Sabarinathan Ramachandran · University Of Minnesota · U19 · FY2023 · AI

Mechanisms of Murine Tumor Eradication by Immunotherapy

$528,643
Philip D Greenberg · University Of Washington · R01 · FY2007 · CA

Antigenic determinants of asthma-associated allergens for design of immunotherapy

$528,625
Anna Pomes · Indoor Biotechnologies · R01 · FY2024 · AI

Matrix assembly and remodeling during S. aureus biofilm development

$528,502
Kenneth W. Bayles · University Of Nebraska Medical Center · P01 · FY2015 · AI

Role of immune receptor clustering in controlling efficacy of antibody-dependent FcγRIIIa-mediated cytotoxicity by NK cells

$528,500
Yuri Sykulev · Thomas Jefferson University · U01 · FY2020 · AI

Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen

$528,498
Moonsoo M. Jin · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA

Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen

$528,498
Moonsoo M. Jin · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · CA

Regulatory T cells in Autoimmune Disease

$528,485
Charles Garrison Fathman · Brigham And Women'S Hospital · U19 · FY2008 · AI

Sunitinib Modulation of Cancer Immunotherapy

$528,446
James H Finke · Cleveland Clinic Lerner Com-Cwru · R01 · FY2012 · CA

Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancer

$528,427
Antonio Jimeno · University Of Colorado Denver · R01 · FY2025 · CA

Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer

$528,416
Tuan Vo-Dinh · Duke University · R01 · FY2022 · EB

Epigenomic Mechanisms & Contextual Immunity in Persistent MRSA Bacteremia

$528,279
Michael R Yeaman · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · U19 · FY2023 · AI

Mechanisms of Antigen-Induced Tolerance in the Lung

$528,200
Anuradha Ray · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI

Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy

$528,183
Gang Zhou · Augusta University · R01 · FY2021 · CA

Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma

$528,175
Fabiana Perna · H. Lee Moffitt Cancer Ctr & Res Inst · R37 · FY2024 · CA

Molecular Genetics

$528,163
Carlo M Croce · University Of California, San Diego · P01 · FY2014 · CA

TCR-antigen foundation model to empower TCR-based diagnostics and therapeutics

$528,157
Tao Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · AI

Metabolic Control of Immune Suppression in Gliomas

$528,130
Maciej S Lesniak · University Of Chicago · R01 · FY2015 · NS

Nanoscale delivery vehicles for antigen-based vaccines

$528,113
University Of California Berkeley · R01 · FY2005 · EB

Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization

$528,041
James R. Heath · Institute For Systems Biology · R01 · FY2023 · CA

Targeting PIM-2 Kinase for Improving Cancer Immunotherapy

$528,033
Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2023 · CA

Targeting gasdermin D to treat myelodysplastic syndromes

$527,987
Peng Ji · Northwestern University At Chicago · R01 · FY2024 · HL